INCORTA
8.6.2021 17:14:04 CEST | Business Wire | Press release
Incorta , the Direct Data Platform™, today announced a multi-year partnership with MDSap , a sub-holding of Midis Group, a global leader in redistributing and reselling, to expand its go-to-market in the Middle East, Turkey, and Eastern Europe and address the region’s growing need for modern analytics and business intelligence. The partnership will provide MDSap’s 400 global enterprise customers with a fast and scalable data analytics solution, bringing Incorta’s Direct Data Platform to key regions such as the Middle East, North Africa, Turkey and Eastern Europe.
The COVID-19 pandemic spurred a rapid increase in the need for advanced technology, and Incorta’s presence in the Middle East is expected to grow by more than 100% this year – a market valued at $11 billion in 2020 and expected to reach $28 billion by 2026. The partnership will help replace outdated, legacy solutions, bringing modern data analytics to new and existing customers at unprecedented speed and scale.
“We’re thrilled to partner with Incorta to bring their state-of-the-art data analytics solution to our enterprise customers,” said Tony Achkar, group managing director of MDSap. “As the Middle East, Turkey and Eastern Europe regions continue to experience rapid digitization, our customers need a modern solution to help them keep up with today’s pace of business. Incorta is allowing them to analyze their data at a level of speed and scale they’ve never seen before.”
As SAP’s gold partner, MDSap leverages SAP technology and other solution providers to help businesses run smoothly and efficiently. Making smart, data-informed decisions is a key part of operating a business, as MDSap customers require the ability to quickly analyze, ingest and then act on their data in order to gain crucial insights about their business. Incorta’s Direct Data Platform will enable users to analyze massive sets of data at lightning speed, allowing them to maximize the full value of their data.
“The Middle East presents exciting opportunities for digital transformation and growth, especially in the data analytics market,” said Incorta CEO Scott Jones. “We are proud to be partnering with MDSap to help more companies in the region innovate and thrive with tools for making the most of their business data.”
The Incorta and MDSap integration is available now.
For more information, visit https://www.incorta.com/partners/mdsap .
About Incorta
Incorta is the only unified data analytics platform powered by Direct Data Mapping™. Purpose-built to help companies stay ahead of the accelerating rate, volume, and complexity of modern enterprise data, the platform delivers unmatched speed and visibility. Incorta is built with open standards and integrates with cloud-friendly tools and platforms, making it easy to consolidate data in the cloud and extract meaningful insights. By making any data source continuously available for analytics, the platform helps business leaders, business teams, and data scientists make more accurate, timely and transparent decisions with faster access to richer data sets. Backed by GV (formerly Google Ventures), Kleiner Perkins, M12 (formerly Microsoft Ventures), Telstra Ventures and Sorenson Capital, Incorta powers analytics for some of the most valuable brands in the world, including Broadcom, Credit Suisse and Shutterfly. To learn more and try it for yourself, visit www.incorta.com .
About MDSap
MDSap, a gold partner of SAP and expert in SAP’s banking solutions, has over 25 years of in-depth experiences helping customers manage, integrate, analyse and mobilize business mission critical data across the enterprise. The company has an exceptional track record providing turnkey IT solutions across the Middle East, Turkey & Central Eastern Europe to over 400 enterprise customers and government entities. MDSap is part of the Midis Group and is a member of EPM International and currently operates 10 offices across the Middle East, Turkey and Central Eastern Europe.
For more information, visit https://www.mdsaptech.com/en/ .
About Midis Group
With more than 5,000 professionals, representing the top 100 global IT vendors, and a solid 50-year track record of performance and reliability, the Midis Group is an international organization of over 170 companies across Europe, the Middle East & Africa. The group is known for its advanced offering of managed IT services and consultancy, system integration, cloud and data center capabilities and infrastructure, software and hardware solutions, as well as technology distribution and retail. It was named in 2006 as one of the World Economic Forum’s initial 100 Global Growth Companies. The group focuses on providing the best in services, with integrity, to vendors, partners, and customers across the destinations it serves. For more information, visit: www.midisgroup.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005870/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom